Wegovy Generic Name: Semaglutide and What It Means

“Generic name” and “generic drug” sound interchangeable, but with Wegovy they mean two very different things — and the difference decides what you can actually buy. Explore the full Peptides & GLP-1 library.

People searching the "Wegovy generic name" often expect that naming the molecule points them to a cheaper equivalent on the shelf. The generic name is semaglutide. Whether an approved generic product exists is a separate question, and as of April 2026 the answer is no. Here is why the two ideas diverge.

Semaglutide: the nonproprietary name behind Wegovy

Every prescription drug has a brand name and a nonproprietary (generic) name. Wegovy is the brand; semaglutide is the molecule. The same semaglutide molecule also carries the brand names Ozempic and Rybelsus under separate FDA labels. Knowing the generic name tells you what the drug is — it does not tell you a lower-cost copy is available.

Why a nonproprietary name is not a generic drug

A generic drug is an approved, interchangeable copy that reaches the market only after patents expire and a regulator signs off. There is no FDA-approved generic semaglutide product today. So while "semaglutide" is the generic name you will see on labels and in studies, buying a true generic of it is not yet possible.

Biologic and peptide approval rules

Semaglutide is a peptide, and peptide and biologic drugs move through a different FDA route than ordinary small molecules. The eventual competitor is likely to be a biosimilar or follow-on product, which must clinically demonstrate similarity in pharmacokinetics, pharmacodynamics, and immunogenicity. Novo Nordisk’s semaglutide patents are expected to expire around 2031–2033, with Eli Lilly’s tirzepatide patents on a comparable timeline.

The compounding lane explained

During the FDA-declared shortages — through late 2024 for semaglutide and early 2025 for tirzepatide — 503A compounding pharmacies legally produced these molecules. Both shortages have been resolved, narrowing but not fully closing that window.

Compounded is a different category

Compounded semaglutide stays available through licensed pathways where clinically justified, yet it is legally and factually distinct from the FDA-approved brand and is not a generic. Potency and formulation vary by pharmacy, so state licensure and provider evaluation matter.

Timeline to a real generic

A genuine generic or biosimilar cannot arrive until the patents lapse and the FDA approves the follow-on. Expectations point to the early 2030s for semaglutide and the early-to-mid 2030s for tirzepatide. Liraglutide patents (Victoza, Saxenda) have already expired in some jurisdictions, putting generic liraglutide closer than generic semaglutide.

If price is the reason you searched

Cost-focused options include the manufacturer savings card for eligible insured patients, discount platforms like GoodRx and SingleCare, patient assistance programs, and licensed compounded formulations where clinically justified. Beneath price sits your own metabolism: variants in FTO, GLP1R, and MC4R shape appetite and energy balance. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights for pathway context — never predicting drug response — alongside PlexusDx Weight Management Protocols such as Semaglutide Oral.

Reading a label: brand versus generic name

On a prescription and in the clinical literature you will see both names in play. The brand — Wegovy — identifies the specific product and indication, while the generic name, semaglutide, identifies the molecule regardless of which brand carries it. Studies and FDA labeling reference semaglutide by that nonproprietary name, which is why the term shows up everywhere even though no approved generic product exists. Recognizing the distinction helps when comparing sources: a paper discussing semaglutide is describing the molecule inside Wegovy, Ozempic, and Rybelsus alike, not signaling that a cheaper generic version is available at the pharmacy counter today.

This is also why matching a coupon or an online listing to your prescription can get confusing: a page advertising “semaglutide” may be pointing to a compounded product, a brand, or simply an educational reference to the molecule. Reading the fine print — and confirming exactly what a seller is offering — keeps the brand-versus-molecule distinction from turning into a purchasing mistake.

Frequently Asked Questions

What is the generic name of Wegovy?

The generic (nonproprietary) name is semaglutide. That is the molecule inside Wegovy, and it is also the active ingredient in Ozempic and Rybelsus under different FDA labels. Knowing the generic name identifies the drug but does not mean an approved generic product is available to purchase.

Can I buy generic semaglutide?

Not as an FDA-approved generic product — none exists as of April 2026. You may encounter compounded semaglutide from licensed 503A pharmacies, but that is a separate regulatory category, not a generic. Verify licensure and confirm a provider has evaluated whether it is clinically appropriate for you.

Why is there a generic name but no generic drug?

Every medication has a generic name from the start; a generic drug only appears after patents expire and a regulator approves an interchangeable copy. Semaglutide is still under patent and follows the biosimilar pathway, so the name exists while an approved generic product does not yet.

When might generic semaglutide appear?

Likely the early-to-mid 2030s, once patents lapse and the FDA approves a biosimilar or applicable small-molecule generic. The exact timing can shift with litigation and regulatory decisions. Until then, savings cards, discount platforms, and licensed compounding are the realistic cost levers to discuss with a provider.

Continue learning inside the PlexusDx Education Hub. Browse more Peptides & GLP-1 education.